Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Debt (2023 - 2024)

Historic Non-Current Debt for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Q4 2024 value amounting to $4.7 million.

  • Tonix Pharmaceuticals Holding's Non-Current Debt fell 2886.76% to $4.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.7 million, marking a year-over-year decrease of 2886.76%. This contributed to the annual value of $4.7 million for FY2024, which is 2886.76% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Non-Current Debt stood at $4.7 million for Q4 2024, which was down 2886.76% from $5.2 million recorded in Q3 2024.
  • Tonix Pharmaceuticals Holding's 5-year Non-Current Debt high stood at $6.6 million for Q4 2023, and its period low was $4.7 million during Q4 2024.